Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIEL-ENGIC: Anti-EGFR Agents in aCRC With Wild-type RAS and Right-PTL
NCT07094893Phase 4Not yet recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of cetuximab in colorectal cancer (CRC), sponsored by Gruppo Oncologico Nord Ovest. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07094893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094893.